Aclaris Therapeutics, Inc. (ACRS)
| Market Cap | 583.08M |
| Revenue (ttm) | 7.83M |
| Net Income (ttm) | -64.92M |
| Shares Out | 139.00M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,303,010 |
| Open | 4.200 |
| Previous Close | 4.410 |
| Day's Range | 4.080 - 4.370 |
| 52-Week Range | 1.160 - 4.890 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 9.80 (+133.61%) |
| Earnings Date | May 7, 2026 |
About ACRS
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational... [Read more]
Financial Performance
In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price target is $9.8, which is an increase of 133.61% from the latest price.
News
Aclaris Therapeutics Transcript: Study update
Full top-line results from the ATI-052 phase I-A trial show strong PK/PD, 100% target inhibition, and excellent safety, supporting infrequent dosing. ATI-2138 advances to phase IIb in lichen planus, targeting both TCR and JAK3, with a basket study design for broad efficacy.
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Ext...
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat...
Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
ATI-052, a bispecific antibody, shows best-in-class potency and extended dosing intervals for atopic dermatitis and asthma, with ongoing studies and no major safety concerns to date. The portfolio includes innovative small molecules and a strategy for combination regimens, with key clinical readouts expected soon.
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat...
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEW...
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat...
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused...
Aclaris Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified pipeline in immunology, with key phase II data readouts for TSLP and bispecific antibodies expected by year-end. ITK inhibitors show strong preclinical and clinical promise, and a robust cash position funds operations into Q4 2028.
Aclaris Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Key clinical programs are advancing, with pivotal data for bosakitug and ATI-052 expected in the second half of the year. Both programs show strong differentiation in potency, dosing, and safety, with potential expansion into multiple indications. 2026 is set as a major milestone year.
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Result...
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The discussion highlighted progress on TSLP-targeted biologics and ITK/JAK3 oral inhibitors, with key clinical readouts expected in late 2026. Next-generation ITK-selective compounds are advancing, aiming for broad efficacy and favorable safety across multiple immune-mediated indications.
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics Transcript: Study Result
ATI-052 showed strong safety, tolerability, and best-in-class PK/PD in a Phase 1A trial, with complete and sustained inhibition of key inflammatory pathways at low doses. The bispecific antibody outperformed comparators and supports extended dosing intervals, with Phase 1B trials in atopic dermatitis and asthma set to begin soon.
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Exten...
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing a diversified pipeline of large and small molecule therapeutics, with major data readouts expected in 2026 across TSLP mAb, IL-4/TSLP bispecific, and ITK inhibitor programs. Strategic study designs and a strong cash position support efficient progress.
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...
Aclaris Therapeutics Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted a robust pipeline with four clinical-stage assets by 2026, including differentiated biologics and next-gen small molecules targeting dermatological and respiratory diseases. Key data readouts are expected in 2026, supported by strong financials.
Aclaris Therapeutics Transcript: Stifel 2025 Healthcare Conference
A clinical-stage biotech highlighted its diversified pipeline, including a potent TSLP antibody (Bosakitug) in phase 2B for atopic dermatitis, a bispecific antibody targeting TSLP/IL-4R, and a next-gen ITK inhibitor for lichen planus. Cash runway extends into late 2028.
Aclaris Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing a diverse immunoinflammatory pipeline, including potent ITK inhibitors and TSLP-based biologics, with major clinical catalysts expected in 2026. Rigorous trial design and a strong cash position support progress across multiple indications.
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Targe...
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammato...